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Abstract 
 
Simple demographic and infectious disease models of buffalo and other domestic hosts for animal 
trypanosomosis (surra) caused by Trypanosoma evansi were developed.  The animal models contained 
deterministic and stochastic elements and were linked to simulate the benefit of control regimes for surra in 
village domestic animal populations in Mindanao, Philippines.  The impact of the disease on host fertility 
and mortality were key factors in determining the economic losses and net-benefit from the control regimes.  
If using a high (99%) efficacy drug in surra-moderate to high risk areas, then treating all animals twice each 
year yielded low prevalence in 2 years; targeted treatment of clinically sick animals, constantly monitored 
(monthly), required 75% fewer treatments but took longer to reach a low prevalence than treating all animals 
twice each year.  At high drug efficacy both of these treatment strategies increased the benefit over untreated 
animals by 81%.  If drug efficacy declined then the benefit obtained from twice yearly treatment of all 
animals declined rapidly compared with regular monitoring and targeting treatment to clinically sick 
animals.  The current control regimen applied in the Philippines of annual sero-testing for surra and only 
treating sero-positive animals provided the lowest net-benefit of all the control options simulated and would 
not be regarded as effective control.  The total net-benefit from effective surra control for a typical village in 
a moderate/high risk area was 7.9 million pesos per annum (US $158,000).  The value added to buffaloes, 
cattle, horses, goats/sheep and pigs as a result of this control was US $88, $84, $151, $7, $114 per 
animal/year, respectively. 
 
Keywords: Trypanosoma evansi; Cost benefit; Control strategies; Targeted treatment; Infectious disease 
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1. Introduction 
 
The epidemiology of Trypanosoma evansi (surra) results from interactions between the main tabanid 
arthropod-vectors (Tabanus spp.), climate, susceptibility of hosts, animal stress and movement, 
pathogenicity of the parasite, and the structure of domestic and wild animal populations (Luckins, 1998; 
Reid, 2002).  In the high surra-risk areas in Mindanao, tabanids are abundant throughout the year 
(unpublished data) facilitating transmission of T. evansi amongst susceptible village buffalo and other host 
animals that are usually tethered together in common pasture areas.  Stress due to farm work and concurrent 
diseases assists the survival of the parasite in animal hosts, while constant movement of animals within the 
island due to trade, a government dispersal programme and transmigration of people favours the spread of 
the disease.  Surra is considered one of the most economically important animal parasitic diseases in the 
Philippines (Manuel, 1998), particularly in Mindanao.  While buffaloes and cattle are believed to be the main 
reservoir hosts for T. evansi harbouring chronic disease, mortality and morbidity may also occur in these 
animals.  Horses are most susceptible to surra, showing acute disease and high mortalities (Silva et al., 
1995), while goats and pigs are also likely to be infected (Manuel, 1998; Reid, 2002; Dargantes et al., 2005: 
Holland et al., 2003). Reduced fertility and mortality were observed in buffalo populations in surra-high risk 
areas (Dargantes et al., 2009).  However, despite the impact of surra on animal productivity, financial losses 
due to the disease are potentially underestimated due to insufficient data, misdiagnosis, remoteness of the 
affected areas, and reluctance of the farmers to report mortalities. 
Surra can only be effectively controlled through the use of curative drugs, which are relatively 
expensive and not widely available.  Of the drugs available only melarsomine hydrochloride (Cymelarsan
R) 
and diminazine aceturate (Berenil
R, Surraplex
R, Trypan
R) are considered safe for use in all animal species.  
Nevertheless, melarsomine is the only drug that has demonstrated satisfactory efficacy in south-east Asia 
(Lun et al., 1991; Payne et al., 1994) but it is not currently marketed in the Philippines.  In recent years, the 
Philippine government has implemented an extensive Mindanao-wide control programme known as the 
Mindanao Unified Surra Control Approach (MUSCA).  It was designed to reduce the incidence of surra in 
endemic areas to avoid further economic losses and to prevent its spread to other provinces.  The programme 
which mainly involved chemotherapy using diminazene, also included educating farmers on the life cycle 
and health impact of surra, capability-building of technicians and regional laboratories for better disease     4 
diagnosis, supportive treatment and disease monitoring.  The endeavour has been successful in reducing 
damage due to the disease (R.T. Mercado, personal communication); however, sporadic epidemics have 
occurred in recent months.  There is therefore a need to assess the economic benefits of the present 
chemotherapy regimen and other practical treatment options in order to justify the continuation of a more 
cost-effective, sustainable control strategy against the disease.  In this study, a disease model for surra in 
village buffalo and other animal hosts was developed to simulate losses due to the disease and evaluate 
financial benefits of six treatment regimens.  Data from a cross-sectional survey of the seroprevalence of T. 
evansi conducted in Mindanao (Dargantes et al., 2009) was used to estimate parameters for the host 
population demographic and infectious disease models.  Treatment costs and the benefits gained by animals 
achieving their full reproductive potential were included in the model as a measure of the productivity from 
village/small-hold farms in the Philippines.  Rate parameters associated with birth, death, disease 
transmission and chemotherapy were treated as random variables for the purpose of Monte Carlo simulation.  
Cost parameters were fixed in the model as the effect of the disease on productivity was the primary concern 
of the study rather than accounting for the impact of fluctuations in market price.  Changes in vector 
populations, normally subject to climate temperature and moisture variables, were modelled in a simplistic 
way by assuming tabanid abundance changed smoothly between preset peak season abundance and 
minimum levels which occurred 6 months after the peak.  Having developed this model for a well-defined 
endemic region it can be applied to other areas where surra poses a risk or it can be used to predict the likely 
dynamics of disease if surra were introduced to a surra-free zone. 
 
 
2. Materials and methods 
 
2.1. Surra/buffalo infectious disease (SIC) model 
For hosts, three disease states were modelled, Susceptible-infectious-subclinical (SIC) -  transition 
between these states was dependent on vector capacity, prevalence, host resilience and chemotherapy as set 
out below.  Data from a 4-year (2002-6) survey of village buffaloes and other animal hosts from five 
provinces in Mindanao, Philippines were used to define the model framework (Dargantes et al., 2009).      5 
Additional initial data from an on-going 2007-8 Mindanao survey of buffaloes, pigs and goats were also 
utilised to estimate the relevance of the host species in the disease epidemiology. 
 
2.1.1. Transition states 
Tables 1-2 and Fig. 1 show the details of the transitions in the SIC model for buffaloes.  Note there is 
no transition from the two infected states (infectious (i) and subclinical (c)) to the uninfected-susceptible 
state, which is a common transition for some bacterial and viral diseases (i.e. susceptible-infectious-resistant-
susceptible (SIRS) models).  However, the simulation model allows for drug treatment and in this case the 
number of infected animals successfully treated in a time-step are moved to the appropriate uninfected 
cohorts (So or Ro, the uninfected innate susceptible and resistant hosts, respectively).  Also, animals cannot 
go directly to a subclinical cohort without first becoming infectious (clinically infected).  The simulation 
model time-step was 1 month and the framework described here for buffalo was used for other hosts by 
changing the relevant production and infection parameters (Table 3). 
 
2.1.2. Vector transmission 
Trypanosoma evansi is mechanically transmitted between buffalo and other host species by tabanid 
flies.  Infection success is dependent on the fly intensity, host susceptibility, disease prevalence and level of 
parasitaemia in infected animals (Desquesnes et al., 2009).  Tabanid intensity or attack rate (arbitrarily set 
with potential range 0 to10) was assumed to be seasonal and defined by a cosine-curve (Fig. 2) with three 
parameters:  maxMonth, max and min which fix the month of maximum fly intensity and the maximum and 
minimum levels, respectively.  The minimum level intensity was assumed to occur 6 months after the 
maximum level, with Vector Intensity (Vi) defined by the cosine-curve as: 
     Vi  =  min+[(max-min)*{1+cos(angle)}/2],   where angle is the month transformed to an angle by: 
 angle  =  (month-maxMonth)*360/12   and month was 1, 2, 3… for Jan, Feb, March etc., note angle is 
converted to radians before use in the cosine function.  The parameters StoI and RtoI are the probability 
that infection will result from a bite from a fly carrying the parasite for the innate susceptible and resistant 
cohorts, respectively.  The transition from susceptible to infectious as determined by the equations shown in 
Tables 1 and 2 is similar to the “frequency-dependent transmission” defined by Begon et al. (2002).  
However here, I/N represents the proportion of infectious animals, not prevalence, because it was assumed     6 
that a proportion of subclinical animals do not have high enough parasitaemia to allow biting tabanids to 
acquire any trypanosomes.  The proportion of subclinical animals that contribute to the total pool of 
infectious animals was determined from the parameter SCinfect (Table 2).  To estimate transmission 
success the proportion of infectious animals (I/N) was further amplified or decreased by Vi to yield V (i.e. 
V=Vi*I/N), which was used in the model as shown in Table 1.  It is not unreasonable for V to exceed one 
as this would indicate multiple contacts with flies carrying infection.  However, if V*StoI or V*RtoI 
exceed one, which is possible at high prevalence and high vector intensities, then this product is reset to one 
as only 100% of uninfected hosts can be converted to infectious.  Vi is a parameter that combines a number 
of parameters associated with the vector such as: fly-host contact rate, the probability that a fly acquires a 
trypanosome(s) from an infected animal, the probability of successfully transferring a viable trypanosomes to 
an uninfected host (vector competence) and fly intensity.  Measurement of all such parameters are currently 
not available so the above seasonally defined Vi between set levels substitutes for a more comprehensive 
exploration of vector competence.  The parameter minN was included to represent a pool of uninfected non-
buffalo hosts (in buffalo equivalents) that are also tabanid targets but generally maintain a lower surra-
seroprevalence than buffaloes (e.g. goats, dogs, pigs etc.).  For large buffalo populations or simulations that 
included these hosts this factor is not applied, as was the case for this study.  However, for small populations 
N is increased to the minimum value if necessary. 
 
2.1.3. Summary 
An arbitrary scale of 0 to 10 was chosen to represent vector intensity (Vi).  Seasonal fluctuations 
between the maximum and minimum levels of Vi (set by the user) was defined by a cosine-curve, this curve 
provides the fly intensity for a particular month.  The Vi value was then reduced by the current proportion of 
infectious animals (I/N) to give V (the monthly transmission coefficient).  However, if N was less than 
minN then the proportion infectious was set to I/minN.  That is, V = Vi*I/minN becomes the monthly 
transmission coefficient for small herds.  Finally, the proportion of uninfected animals that became infected 
in a particular month was V*StoI and V*RtoI for the innate susceptible and resistant hosts, respectively. 
 
2.1.4. Drug treatment, animal harvest and import     7 
The efficacy of the drug, the proportion of each cohort treated and frequency of treatment were 
control/user-defined management parameters (see Table 2).  The proportion of animals successfully treated 
(e.g.  Efficacy*TreatI) in a particular time step was removed from the infected groups and returned to 
the uninfected groups; no immunity was assumed to be conferred by prior infection (Donelson et al., 1998).  
If the number of drug treatments/year were set at 0.5, 1 or 2… then a simulation treatment would be 
scheduled once in 24, 12 or 6… months etc.  Annual birth and death rates were converted to monthly rates, at 
each time step the number of dead animals was removed from each cohort, and then excess males (or 
females, depending on the set sex ratio) were removed (harvested), as calves, to maintain the initial sex ratio.  
If the resulting population exceeded the initial population then additional animals were harvested, or if 
necessary animals were imported to maintain the original herd size.  Any animals imported were assumed to 
be uninfected.  The model was developed in Excel (Microsoft Inc., USA). 
 
2.1.5. Cattle, horse, sheep/goat and pig hosts 
The SIC model described above was also used to simulate infections in non-buffalo hosts by 
changing the relevant parameters (see Table 3).  Separate Excel workbooks for each host species were 
opened simultaneously to exchange information on host numbers and vector intensity.  A Relative Host-
Vector Ratio was defined to convert different host to buffalo equivalents for the purpose of estimating vector 
transmission and the ratio of infectious to uninfected animals for all host species at risk in an area; this is 
similar to that described by Doran et al. (2005) for viral disease in feral pigs.  This ratio was defined as the 
number of non-buffalo animals that attracted the same number of flies that were on one buffalo, (e.g. if a 
buffalo had attracted 60 flies while a cow attracted 30 flies then two cows was equivalent to one buffalo and 
the cow ratio would be set at 2).  The proportion of infectious animals (I/N) was determined by converting 
all hosts to buffalo equivalents using the relative ratios shown in Table 3, the composite estimate of I/N was 
used as described above.  The relative ratios were also used to scale the attack rate per host species, e.g. if the 
vector intensity (Vi) was 5 (for buffalo) then it was scaled to 2.5 and 0.5 for cattle and goats respectively 
using the ratios from Table 3.  However, I/N remained common for all species.  Like Vi, the Relative 
Host-Vector Ratio simplifies a number of complex issues into a single parameter, e.g. host size, tabanid host-
specificity, hosts defensive activities and animal management practices.  The latter is likely to play a major 
role in determining the exposure of animals to tabanids.  Manresa et al. (1935) found oxen on open pasture     8 
attracted 18 times more tabanids than oxen under shelter.  The estimates used here are based on anecdotal 
observations by veterinarians visiting surra outbreaks in Mindanao (expert opinion) and take into account the 
local management of the different host species. 
 
2.2.  Evaluation of control regimens with the SIC model 
The SIC model was used to estimate the success of different treatment regimens in a typical village 
of moderate/high surra risk and included buffaloes, goats/sheep, pigs, horses and cattle as these are the 
animals of major economic or production importance.  Simulations were run for 15 years, however, results 
focused on the first 5 years after intervention.  Six drug treatment regimens were simulated: (1) twice yearly 
treatment of all animals; (2) twice yearly treatment of horse, cattle and buffalo (goat and pigs remained 
untreated); (3) targeted treatment of all animals showing clinical signs, monitored monthly; (4) targeted 
treatment of horses, cattle and buffaloes showing clinical signs (goats and pigs remained untreated), 
monitored monthly; (5) annual diagnostic testing of buffaloes, cattle and horses, and only treating sero-
positive animals; (6) no treatment of any hosts.  Regimens 1-4 were considered realistic practical options for 
Mindanao.  Regimen 5 is currently applied in Mindanao but in practice additional treatments are also applied 
in response to a disease outbreak.  For regimens 1-5 drug efficacy was assumed to be 99% (i.e. for 
melarsomine); regimen 5 was also simulated with the efficacy set to 80% (regimen 5a) to represent 
diminazene aceturate use. 
To simulate these regimens, additional assumptions were made.  When estimating the total number 
of drug treatments required for regimens 1-5, drug treatment was stopped for a host species when no new 
clinical cases occurred in that species.  For regimens 1-2 it was assumed that 100% of the host species 
targeted for treatment received treatment.  The true cohort of clinically sick animals is shown in Table 1, 
however allowance was made for incorrect diagnosis at the time of treatment for regimens 3-4.  Thus the 
drug treatment parameter values given in Table 3, for regimens 3-4, are the proportion of animals actually 
treated (when aiming to treat all clinically sick animals); these were set at 0.95, 0.2 and 0.03 for clinical, 
subclinical and uninfected animals, respectively.  For regimen 5, the treatment of sero-positive animals is 
dependent on the sensitivity and specificity of the diagnostic test used; we set the proportion of clinical, 
subclinical and uninfected animals treated to 0.83, 0.83 and 0.04,  respectively.  This assumes 83%     9 
sensitivity, 96% specificity (Reid and Copeman, 2003) based on the card agglutination test for T. evansi 
(CATT; Institute for Tropical Medicine, Antwerp, Belgium). 
For Monte Carlo estimates of treatment outcomes, model parameters for proportion of animals 
treated, birth, death and transition rates were randomly varied for 500 simulations to estimate mean model 
results and their 95% confidence limits.  Random selection for the parameters was from a pert distribution 
with the most likely value being that given in Table 3 or as described above.  Random variables and Monte 
Carlo simulation were generated using PopTools (CSIRO, Australia) within Excel.  The impact of drug 
resistance or using a low efficacy drug in regimens 1-4 was examined by setting drug efficacy to 100, 99, 95, 
90, 80, 70…0% in additional simulations for these regimens. 
 
2.3.  Cost benefit analysis 
The net-benefit for each drug regimen was obtained by subtracting the cost/benefit result for the 
untreated simulation (6) from the cost/benefit result for the drug treatment regimens (1 to 5), this was done to 
simplify the cost/benefit analysis by ignoring common costs and benefits.  Because all species were 
maintained at a fixed level in the simulations, some common costs/benefits were assumed to be 
approximately equal.  That is, let T, M and R represent animal Treatment, Maintenance and Replacement 
costs, respectively, and D, C and E represent benefits from animal Draft-power, Consumption and Export, 
respectively. If Bt and Bu are the benefits from treated and untreated regimens, respectively, then the net-
benefit for a treatment regimen (Bt-Bu) is given by:  
  Bt-Bu = Dt-Du + Ct-Cu + Et-Eu - Tt -Mt+Mu -Rt+Ru      this reduces to: 
  Bt-Bu = Et-Eu - Tt  -Rt+Ru      if we assume that under both regimens: (a) draft-power 
requirements are sufficient; (b) consumption of animals are similar; and (c) maintenance cost are similar. 
Thus the simplified cost/benefit analysis for each regimen needs only to account for T (drug purchase, 
application and test costs), R (purchase of replacement animals when needed) and E (sale of excess animals 
when available) if we only estimate the net-benefit for each treatment regimen.  This represents a reasonable 
approximation, although healthy animals may have more draft capacity than untreated animals (i.e. Dt-
Du≥0); in contrast an increased turnover of pigs, for example, expected for effective treatment regimens, 
would possibly require increased feed inputs (i.e. -Mt+Mu≤0) while increased animal consumption due to 
improved fertility providing excess animals is accounted for as an export benefit.      10 
The average benefit/host (mean of the benefit of the five host types) in pesos was determined for 
each drug treatment regimen and the untreated hosts (i.e. {∑Bi}/5 where Bi was the mean benefit/year for 
host type i and i=1…5).  The total benefit for a regimen was estimated by: 
  Total benefit = ∑Ni*Bi     where Ni was the number of animals of host type i and i=1…5. 
 
 
3. Results 
 
3.1. Surra/buffalo SIC model 
 
3.1.1. Buffalo, cattle, horse, sheep/goat and pig hosts 
Table 4 shows long-term predicted prevalence in untreated animals for a range of vector intensities.  
Because buffalo were the primary survey target, relatively few non-buffalo hosts were sampled (see Table 2 
in the accompanying paper by Dargantes et al. (2009)).  Using the observed seroprevalence in buffaloes from 
Table 2 in the Dargantes et al., 2009 report as a reference point, a comparison between long-term modelled 
prevalence (Table 4) and observed seroprevalence for other host-species can be made.  There was some 
reasonable agreement for cow, horse and pig prevalence.  The observed seroprevalence in goats/sheep was 
moderate and low when the observed buffalo seroprevalence was high.  However, the predicted prevalence 
in goats/sheep was relatively low for a broad range of buffalo seroprevalence.  In Table 4, modelled horse 
prevalence is similar to cattle at low vector intensities but becomes higher than cattle at high vector intensity.  
This result was based on the need in the model for sustained import of horses to maintain the population in 
high vector intensity areas.  If imports ceased, then horse populations rapidly died out, which is what has 
been observed in Mindanao in high risk areas (A.P. Dargantes personal communication). 
 
3.2.  Evaluation of control regimens with the SIC model 
  Table 5 gives the number of drug treatments required to prevent clinical disease (in the first 5 years) 
under each regimen for each host species (deterministic result using the most likely parameter value and 
stochastic results).  The 95% confidence limits in Table 5 indicate that targeted treatment of clinically sick 
animals, monitored 12 times/year, required significantly fewer treatments than treating all animals twice per     11 
year, i.e. regimens 3 and 4 had upper confidence limits less than 300 total treatments while regimens 1 and 2 
had lower confidence limits greater than 500.  Leaving pigs and sheep/goats untreated required 
approximately five-fold more buffaloes to be treated under the two treatments/year regimen (1 versus 2) and 
two-fold more under the targeted treatment regimen (3 versus 4) (see Table 5).  For each host species and 
control regimen the predicted prevalence averaged over the first 5 years is given in Table 6.  For regimen 5, 
prevalence was approximately halved (depending on host species) while regimens 1-4 generally reduced 
prevalence to less than 6%.  The net-benefit from the five drug treatment regimens by comparison with 
untreated hosts are shown in Fig. 3.  Because the net-benefit was derived by subtracting the benefit/cost of 
untreated animals (6) from each regimen (1 to 5) then in host or treatments with 95% net-benefit confidence 
limits that do not overlap with zero (x-axis) are significantly different from untreated animals (Fig. 3). 
 
3.3.  Cost benefit analysis 
For a drug of 100% efficacy the mean benefit/host (averaged over benefit for host type) for regimens 
1 to 6 was 11,527, 10,318, 11,527, 10,731, 8,960 and 6,355 pesos, respectively, i.e. the mean benefits for 
regimens 1 and 3 were both 81% larger than the benefit for untreated animals.  The current practice of annual 
treatment of sero-positive buffaloes, cattle and horses only yielded a 40% improvement, even though the 
drug was assumed to provide 100% efficacy; in practice the efficacy is about 80%.  Fig. 4 shows the 
increased mean benefit from untreated animals for regimens 1 to 4 at various drug efficacies.  As drug 
efficacy declines the benefit for animals treated twice each year, regardless of disease status, declined 
steadily while little loss of benefit occurred for animals monitored monthly and treated if clinically sick (Fig. 
4).  At 50% efficacy the mean benefit/host was 8,935, 8,110, 11,182 and 10,370 pesos for regimens 1 to 4, 
respectively, i.e. about half the gain provided by treatments 1 and 2 was lost while less than 10% of the gain 
made by treatments 3 and 4 was lost due to reduced drug efficacy.  The total benefit (sum of the benefit for 
all animals in a village) for untreated (6) and effective treated (1 or 3) regimens were 1.5 and 9.4 million 
pesos per annum, respectively. That is, the total net-benefit lost to a village by not applying effective surra 
control was 7.9 million pesos per annum or US $160,000/year (assuming 5,000 pesos is approximately US 
$100).  In terms of the value added to the domestic livestock this was estimated to be US $88, $84, $151, $7, 
$114 per animal/year for buffaloes, cattle, horses, goats/sheep and pigs, respectively (deterministic result).      12 
The means for the stochastic results are given in Fig. 3 in pesos; note the stochastic results tend to be slightly 
higher than the deterministic results. 
 
 
4. Discussion 
 
The advantage of using Excel to model an infectious disease is that irregular treatment regimens can 
be easily introduced to the simulation study by changing the column value associated with treatment.  The 
ability to simultaneously model a number of host species, exposed to a common vector base, with an 
infectious disease model over a time-frame sufficient to forecast the demographic impacts on host 
populations has allowed the benefit of surra control on production to be assessed at the village or province 
level.  The benefits estimated here are likely to be conservative because they do not account for reduced 
weight gain and milk yields associated with T. evansi infection, nevertheless there were substantial benefits 
from controlling surra in buffaloes, cattle and horses.  The greatest variation in net-benefit was for pigs 
because small changes in fertility due to disease were amplified by the relatively large litter size and the 
short gestation.  Horses also showed large variation because of their relatively high death rate when exposed 
to surra and their high replacement costs. 
The model predicts that regular monitoring and targeted treatment of all clinically sick animals 
(including sheep/goats and pigs) was the best option, requiring few treatments to produce a low prevalence 
(Table 5-6).  However, in practice this would require proper education of farmers as to the economic 
significance of surra and its symptoms, commitment by stock owners to detect and report the disease to 
authorities through an effective reporting system and the availability of drugs to be administered regularly if 
necessary.  Treatment of all animals twice per year provides similar net-benefits to targeted treatment 
without the need for constant monitoring of animals at risk but this regime needs an initial high input cost 
sufficient to treat all animals and was dependent on using a drug with high efficacy (Fig. 4).  Another 
disadvantage of this option is that systematic mass chemotherapy will increase the risk of selection for drug 
resistance (Uilenberg, 1998); drug resistance is a problem in trypanosomes in African and other Asian 
countries (El Rayah et al., 1999; Zhou et al., 2004) and may emerge in Mindanao under such a regimen.  
From Fig. 4 it is clear that if a drug of low efficacy is used or efficacy declines due to drug resistance, then     13 
the best option is to regularly monitor and treat only clinically sick animals.  Treating pigs and sheep/goats 
was important for disease control because leaving them untreated prolonged the period of new clinical cases 
in other hosts.  However there was little financial benefit from the treatment of sheep/goats if considered in 
isolation from other hosts. 
In conclusion, the model predicts that under the current surra control practice in the Philippines 
changing from a drug of low efficacy to one of high efficacy would only provide marginal benefits, if any, to 
farmers.  However, treating all animals twice per year or regular monitoring and the targeted treatment of 
any clinically sick animals with a drug of high efficacy would provide a substantial benefit.  Of these 
options, targeted treatment is recommended because there are reduced input costs, less labour, better 
trypanocidal activity in the face of declining efficacy and reduced risk of selection for drug resistance.  This 
strategy would also be suitable in other countries where small-hold farmers routinely tether or house their 
stock overnight  In this situation regular assessment of the animal’s health would not impose additional 
animal-management demands on farmers. 
This model is suitable for use in countries where surra is endemic (South-east Asia, India, Africa and 
Latin America) and can be applied at a village or regional scale.  With minor modifications it could be 
applied to other mechanically-vector transmitted diseases similar to that suggested by Desquesnes et al. 
(2009).  The model is currently being developed to include additional host species such as macropods and 
camels so it can be applied to Australian conditions where introduction of surra from south-east Asia is a 
potential bio-security threat.  It will be used to explore various surra-outbreak scenarios to predict the likely 
disease prevalence in reservoir species, change in mortalities of susceptible species, host demographic 
changes and explore potential control/eradication options. 
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Tables 
 
Table 1 
Simplified difference equations for resulting change (Δ) in cohort size in one time-step but not showing birth 
of calves and removal of dead and/or harvested animals from the cohorts. 
 
 Cohort       Change  =       Uninfected * proportion       - losses      + gains 
Uninfected    ΔSo  =    ((1-Innate)*Yo)*(1-V*StoI) - V*StoI*So 
Uninfected    ΔRo  =        (Innate*Yo)*(1-V*RtoI) - V*RtoI*Ro 
 
Clinical         ΔSi  = ((1-Innate)*Yo+So)*(V*StoI)   - Si*ItoC   + Sc*CtoI 
Clinical         ΔRi  =     (Innate*Yo+Ro)*(V*RtoI)   - Ri*ItoC   + Rc*CtoI 
 
Sub-Clinical   ΔSc  =                               - Sc*CtoI   + Si*ItoC 
Sub-Clinical   ΔRc  =                               - Rc*CtoI   + Ri*ItoC 
 
 
Cohort size is represented by So,Ro,Si,Ri,Sc,Rc and Yo(calves), where S and R stand for innate 
susceptible and resistant adults, respectively.  Parameter definitions are given in Table 2.  After drug 
treatment the proportion of animals that are successfully cured are moved to the appropriate uninfected 
cohort (not shown in these equations). 
     18 
Table 2 
Parameters, definitions and symbols used in the buffalo susceptible-infectious-subclinical (SIC) model and 
Table 1.  Rate parameters are given as annual rates.  The range indicates the allowable input minimum and 
maximum limits for the parameters which are sufficiently wide to allow simulation of a variety of hosts. 
 
Parameter  Value & range    Comment 
Innate  0.1  0-1  Proportion with innate resistance 
StoI    0.8  0-1  Infection success for uninfected innate susceptible 
RtoI    0.2  0-1  Infection success for uninfected innate resistant 
ItoC    1.0  0-1  Transition proportion from infectious to subclinical 
CtoI    0.5  0-1  Transition proportion from subclinical to infectious 
a Sex   0.7  0-1  Female proportion of the population 
Birth Rates 
μro    0.475  0-40  Uninfected resistant-Ro female 
μso    0.475  0-40  Uninfected normal-So female 
μi    0.150  0-40  Infectious Si & Ri females 
μc    0.150  0-40  Sub-clinical infected Sc & Rc females 
Death Rates 
λy    0.115  0-1  Calf uninfected Yo 
λro    0.115  0-1  Uninfected resistant Ro 
λso    0.115  0-1  Uninfected normal So 
λi    0.250  0-1  Infectious Si & Ri 
λc    0.175  0-1  Sub-clinical infected Sc & Rc 
Drug treatment 
TreatI  0.95  0-1  Proportion of Infectious animals treated 
TreatC  0.20  0-1  Proportion of Sub-clinical animals treated 
TreatY  0.03  0-1  Proportion of Uninfected animals treated 
a Efficacy  0.99  0-1  Proportion of treated animals rendered uninfected     19 
a Drug  12  0-12  Number of drug treatments/year 
Infection Dynamics  
a minN  33  5-50  Minimum population for disease stability 
a maxMonth  5  1-12  Month in which the maximum fly intensity occurs 
a Vi    2 to 5  0-10  Arbitrary measure of Vector Intensity 
SCinfect  0.2  0-1  Proportion of subclinical animals that are infectious 
a V = Vi*I/N      Vector transmission (for N >= minN) 
a V = Vi*I/minN      Vector transmission (for N < minN) 
a N = So+Ro+Si+Ri+Sc+Rc+Yo    Total buffalo population 
a I = Si+Ri + SCinfect*(Sc+Rc)  Number of infectious animals 
 
a Indicates parameters/quantity were not subject to Monte Carlo simulation (stochastic) variation. 
Note: all clinically sick animals were assumed to be infectious and a proportion of sub-clinical animals were 
infectious.     20 
Table 3 
The number of hosts per village, the relative attractiveness of host to vectors (the larger the number, the 
fewer tabanids/host), modified parameters to simulate disease in non-buffalo hosts and cost benefit analysis 
parameters. 
Parameter or Value  Buffalo  Cattle  Horse  Sheep/Goat  Pig 
a Number of hosts (Ni)  80  40  15  150  200 
a Relative Host-Vector Ratio  1  2  1  10  12 
Birth Rate  0.475  0.500  0.40  1.50  18 
Infected Birth Rate  0.150  0.150  0.10  0.30  5 
Death Rate  0.115  0.080  0.07  0.14  0.1 
Clinical Death Rate  0.250  0.330  0.80  0.50  0.4 
Subclinical Death Rate  0.175  0.175  0.80  0.50  0.4 
Infection Rate Innate Susceptible Host  0.2  0.1  0.2  0.2  0.2 
Infection Rate Innate Resistant Host  0.8  0.5  0.9  0.8  0.8 
a Cost/Benefit Parameters (Pesos)           
Diagnostic cost per test  300  300  300  300  300 
Drug costs per treatment  300  300  300  30  200 
Labour cost per treatment  300  300  300  150  150 
Sale or purchase price of replacement host  25000  25000  10000  1500  5000 
 
a Indicates parameters/quantity were not subject to Monte Carlo simulation (stochastic) variation.     21 
 Table 4 
The effect of increasing vector intensity on the long-term prevalence in untreated hosts.  The fly intensity 
fluctuates between the given high and low value (see the cosine-curve in Fig. 2). 
Fly  Model prevalence, long term in untreated hosts 
Intensity  Buffalo  Cow  Horse  Goat  Pig 
0 to 2  41%  13%  12%  3%  2% 
Set at 1.6  59%  25%  24%  6%  5% 
2 to 5  74%  46%  47%  15%  14% 
5 to 8  80%  59%  64%  27%  24% 
8 to 10  81%  63%  71%  34%  31%     22 
Table 5 
The total number of drug treatments used in the first 5 years for regimens 1-5 and 5a.  The deterministic 
result of the model is given under the column labelled ‘Model’; the other columns give the mean (total 
number) and lower and upper 95% confidence limits (LCL, UCL) from 500 random simulations (Monte 
Carlo). 
   Number of Drug Treatments    Number of Drug Treatments 
Host  Model  Mean  LCL  UCL    Model  Mean  LCL  UCL 
  
aRegimen 1     Regimen 2 
Buffalo  156  271  154  790    783  715  462  790 
Cattle  78  79  77  80    77  198  77  397 
Horse  28  33  26  59    86  100  25  150 
Sheep/Goat  289  311  285  577    0  0  0  0 
Pig  322  350  310  628    0  0  0  0 
Total #  873  1044  852  2134    946  1013  564  1337 
   Regimen 3     Regimen 4 
Buffalo  71  76  66  110    151  161  93  227 
Cattle  27  27  26  29    27  28  26  41 
Horse  4  5  1  8    5  6  2  13 
Sheep/Goat  59  61  55  68    0  0  0  0 
Pig  70  70  62  78    0  0  0  0 
Total #  231  239  210  293    183  195  121  281 
   Regimen 5     Regimen 5a (80% efficacy) 
Buffalo  157  166  81  252    189  188  106  258 
Cattle  40  42  25  62    48  50  34  69 
Horse  19  18  4  37    22  21  6  40 
Sheep/Goat  0  0  0  0    0  0  0  0 
Pig  0  0  0  0    0  0  0  0 
Total #  216  226  110  351    259  258  146  367     23 
aRegimens 1-5 assume a drug of 99% efficacy.  Regimen 1: All animals treated twice/year.  Regimen 2: 
Buffaloes, cattle and horses treated twice/year.  Regimen 3: Targeted treatment of all clinically sick animals 
12 times/year.  Regimen 4: Targeted treatment of clinically sick buffaloes, cattle and horses 12 times/year.  
Regimen 5: Annually test and treat sero-positive buffaloes, cattle and horses.  Regimen 5a: Annually test and 
treat sero-positive buffaloes, cattle and horses with an 80% efficacy drug.     24 
Table 6. 
The mean prevalence, for each regimen, over the first 5 years of treatment.  Results are for the deterministic 
solution using the model parameters given in Table 3. 
  Mean Prevalence Results for Years 1-5 
Regimen  Buffalo  Cattle  Horse  Sheep/Goat  Pig 
                      Initial Starting Prevalence  70.0%  55.0%  60.0%  20.0%  15.0% 
1) 2 Treatments/Year all hosts  4.4%  3.2%  3.4%  1.1%  0.9% 
2) 2 Treatments/Yr. Buffalo, Cattle, Horse  5.8%  3.5%  4.9%  7.0%  6.6% 
3) Targeted treatment of Clinical Animals  5.4%  4.1%  3.8%  1.4%  1.1% 
4) Targeted Clinical Buffalo, Cattle, Horse  5.6%  4.1%  4.0%  6.7%  6.4% 
5) Treatment of sero-positive animals  25.6%  10.5%  20.5%  10.9%  9.8% 
5a)
 a Treatment of sero-positive animals  38.1%  16.7%  29.2%  13.0%  11.5% 
6) No animals treated  74.9%  50.6%  49.9%  17.6%  15.2% 
aA drug with 80% efficacy was used in regimen 5a; in regimens 1-5 the drug efficacy was set at 99%.   
Note: Regimens 1-2 represent mass chemotherapy; Regimens 3-4 are targeted treatments requiring monthly 
monitoring; Regimens 5-5a are annual targeted treatments based on sero-testing.     25 
Figures 
Legends to Figures 
 
Fig. 1.  Susceptible-infectious-subclinical (SIC) Buffalo - Trypanosoma evansi Model. In the SIC model o, i 
and c indicate uninfected-susceptible, infectious (clinical infection) and subclinical-infected animals, 
respectively; lines pointing back to “Yo” indicate reproduction rate; lines cycling within a cohort indicate 
survival rate in that stage; lines connecting stages indicate survival and transition rate from stage to stage.  
Death rates for each stage are not shown.  For simplicity this is not an age structured model.  ‘Innate 
Resistant’ are a cohort of the population that are able to be infected but are more resistant to infection that 
the ‘Innate Susceptible’ cohort; if the innate-resistant-fraction (denoted Innate) is set to zero then the model 
simplifies to the lower four nodes in the diagram (i.e. Yo, So, Si and Sc).  Note drug treatment, death and 
harvest rates of animals are included in the overall model but are not shown in the above simplified diagram 
or in Table 2 which sets out the equations for change at each time-step for this model. 
 
Fig. 2.  Observed tabanids caught on buffalo in open pasture (Manresa and Mondonedo, 1935), the raw data 
(Tabanids/host/hour ranges from 3 to 42) was scaled by dividing the observed values by 42 (shown as “●”).  
The line shows the cosine-curve when the three parameters values were: maxMonth = 4, max = 0.6 and min = 
0.07.  The curve was defined as:  Scaled Tabanids/host/hour  =  min+[(max-min)*{1+cos(angle)}/2],  where 
angle in radians is the month transformed to an angle by:    angle  =  (month-maxMonth)*360/12   and month 
is 1, 2, 3… for Jan, Feb, March etc. 
 
Fig. 3.  Mean and 95% Monte Carlo Confidence Interval of the net-benefit for the five drug treatment 
regimens, using a drug with 99% efficacy.  The net-benefit was obtained by subtracting the cost/benefit 
result for the untreated simulation (regimen 6) from the cost/benefit result for other regimens (1-5), thus 
hosts or regimens with 95% confidence limits that do not overlap with zero (x-axis) are significantly 
different from untreated animals.  Regimen 5a is the same as regimen 5 but with a drug of 80% efficacy. 
 
Fig. 4.  The effect of declining drug efficacy on the benefit obtained for drug treatment regimens 1 to 4.  The 
relative benefit is shown as the percentage improvement in mean benefit per host compared with untreated     26 
animals (regimen 6).  Regimens shown by × indicate only buffalo, cattle and horses were treated, ▲ 
indicates the treatment of all host species, the broken line (---) indicates two drug treatments per year and the 
solid line (——) shows regimens for the targeted treatment of clinically sick animals when monitored 
monthly.     27 
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Figure 2 
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Figure 3 
 
(1) Net Benefit of treating all animals twice a year.
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(2) Net Benefit of treating horse, cattle and buffalo twice a year.
-10000 
-5000 
0
5000
10000
15000
20000
Buffalo Cattle Horse Sheep/Goat Pig
P
e
s
o
s
/
A
n
i
m
a
l
/
Y
e
a
r
 
(3) Net Benefit of treating all clinically sick animals monthly.
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(4) Net Benefit of treating clinical buffalo, cattle and horse monthly.
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Figure 3 (continued over page)     30 
(5) Net Benefit of annual testing and treating sero-positive. Drug 99% efficacy.
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(5a) Net Benefit of annual testing and treating sero-positive host. Drug 80%efficacy.
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Figure 4 
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